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Abstract
Background: The regulation of apoptosis under basal (non-stress) conditions is crucial for normal mammalian development
and also for normal cellular turnover in different tissues throughout life. Deficient regulation of basal apoptosis, or its
perturbation, can result in impaired development and/or disease states including cancer. In contrast to stress-induced
apoptosis the regulation of apoptosis under basal conditions is poorly understood. To address this issue we have compared
basal- and stress-induced apoptosis in human epithelial cells of normal and cancerous origins. For this purpose we focussed
our study on the opposing pro-apoptotic JNK/anti-apoptotic NFkB pathways.
Methodology/Principal Findings: Combinatorial RNAi plus gene knockout were employed to access and map basal
regulatory pathways of apoptosis. Follow-on, in-depth analyses included exogenous expression of phosphorylation mutants
and chromatin immunoprecipitation. We demonstrate that basal apoptosis is constitutively suppressed by JNK2 in a range
of human cancer cell lines. This effect was not observed in non-cancer cells. Silencing JNK2 by RNAi resulted in JNK1-
dependent apoptosis of cancer cells via up-regulation of the AP-1 factor c-Jun. Unexpectedly we discovered that JNK1 and
c-Jun promote basal apoptosis in the absence of ‘‘activating phosphorylations’’ typically induced by stress. Hypo-
phosphorylated c-Jun accumulated to high levels following JNK2 silencing, auto-regulated its own expression and
suppressed expression of Bcl-3, an unusual IkB protein and regulator of NFkB. Basal apoptosis was mediated by
components of the TNFa response pathway but was mechanistically distinct from TNFa-induced apoptosis.
Conclusions/Significance: Our results demonstrate that mechanistically distinct pathways operate to regulate apoptosis in
mammalian cells under basal (physiological) versus stress-induced conditions. We also describe a novel apoptotic network
which governs the basal survival of cancer cells. Such information is crucial for understanding normal cellular turnover
during mammalian development and subsequently throughout life. This information also opens new avenues for
therapeutic intervention in human proliferative disease states including cancer.
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Introduction
The c-Jun N-terminal kinases (JNKs) are members of the mitogen-
activated protein kinase family (MAP kinases, MAPKs) and are
activated in response to cellular stress [1,2]. In response to stress
JNK1 and JNK2 are activated via dual phosphorylation of T183 and
Y185 by MAPK kinases (MAPKK), specifically MKK4 and MKK7
[3,4]. MAPKs and MAPKKs form part of a signal transduction
super-family that includes the extracellular signal-regulated kinases
(ERKs) and p38 MAPK. The functions of JNK1 and JNK2 are
determined by cell type and by the nature of the stress responsible for
their activation. Initial studies identified JNKs by their ability to
phosphorylate the N-terminus of c-Jun, a member of the activating
protein 1 (AP-1) transcription factor family [5]. Subsequently JNKs
were shown to phosphorylate and regulate the activity of other AP-1
proteins as well as additional proteins involved in cell proliferation
and apoptosis including p53, c-Myc, Bcl-2 and Bim [2,6].
AP-1 factors are a group of structurally and functionally
relatedmembers of theJunproteinfamily(c-Jun, JunBand JunD)
and the Fos protein family (c-Fos, FosB, Fra-1 and Fra-1) [7].
Dimerisation within these family members forms an AP-1
transcription factor and the relative abundance of individual
AP-1 subunits and dimer composition are important factors
determining cell fate. The repertoire of AP-1 dimer composition
allows tailoring of an AP-1-mediated response by individual cell
types to a given stimulus. Post-translational modification and
protein turnover are two mechanisms for regulating AP-1
activity. For example, in response to stress the transactivation
potential of c-Jun is activated by JNK-mediated N-terminal
phosphorylation [8,9], whereas the stability of c-Jun protein is
down-regulated via GSK-3-mediated C-terminal phosphoryla-
tion which targets c-Jun for ubiquitinylation and degradation via
t h eE 3l i g a s eF b w 7[ 1 0 ] .
An important activator of the JNK apoptotic pathway is
tumour necrosis factor a (TNFa), a pro-inflammatory cytokine
that governs cell survival via promoting either cell proliferation or
apoptosis [11]. TNFa engages with its trimeric receptor, TNFR1,
at the external surface of the cell membrane. TNFa/TNFR1
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protein complex (complex 1) at the cytoplasmic tail of TNFR1. In
its turn this complex leads to activation of JNK and also of IkB
kinase (IKK). Elegant studies in vitro and in vivo have demonstrated
that, in hepatocytes exposed to TNFa, activated JNK1 phos-
phorylates and activates the E3 ubiquitin ligase ITCH [1,12].
Activated ITCH induces ubiquitinylation and degradation of
cFLIP (cellular FLICE-inhibitory protein) which otherwise
specifically inhibits activation of pro-caspase 8 (also called
FLICE). Caspase 8 activation results in apoptosis [1,10]. This
pro-apoptotic pathway is counter-balanced by NFkB which up-
regulates c-FLIP expression and thus inhibits pro-caspase 8
activation and apoptosis [13].
NFkB is a transcription factor composed of homo- or
heterodimers of members of the Rel family of proteins, including
p65 (RelA), RelB, c-Rel, p50 and p52 (reviewed in [14].
Transcription activation domains are absent in p50 and p52
which thus need to form heterodimers in order to transactivate
target genes. The principal assembly is a heterodimer of p65–p50
but different dimer compositions are also formed. NFkB is subject
to regulation by protein-protein interactions with IkB proteins.
IkBa and IkBb preferentially target p65–p50 heterodimers.
Phosphorylation of IkBb yI kB kinases triggers IkB degradation
with release of dimeric NFkB which translocates into the nucleus
and regulates gene expression. Bcl-3 is an unusual IkB which
preferentially binds p50–p50 and p52–p52 NFkB homodimers
[15,16]. Bcl-3 is further distinguished from other IkB proteins in
that it can localise to the nucleus, it is not degraded upon
activation of NFkB and it possesses seven, rather than six, ankyrin
repeat domains. Nuclear localisation of Bcl-3 is compatible with its
ability to form a ternary complex with DNA-bound p50:p50
homodimers of NFkB, and also to assist uptake of p50 into the
nucleus (see [17] and references therein). Bcl-3 was first described
in B-cell chronic lymphocytic leukaemia [18] and is regarded as a
putative oncoprotein.
In addition to their roles in the stress response JNK1 and JNK2
also function under basal, non-stress conditions as evidenced by
tissue-specific abnormalities observed in JNK12/2 and JNK22/2
mice. For example, JNK12/2 mice exhibit decreased T-cell
differentiation and defective immunity [19]. ImportantlyJNK12/2
mice also develop spontaneous intestinal tumours, indicating that
JNK1 functions as a tumour suppressor for this tissue type [20].
However, the mechanisms of JNK1 and JNK2 functioning under
basal, physiological conditions are poorly understood.
To investigate the individual roles of JNK1 and JNK2 in
human epithelial cells under basal conditions we employed a
combination of (i) RNAi induced in the absence of applied stress,
(ii) gene knock-out cell lines, and (iii) exogenous gene expression.
In a range of human cell lines we discovered that JNK1 is actively
pro-apoptotic but is constitutively inhibited by the presence of
JNK2 in cancer cells. This effect was not observed in non-cancer
cells. Co-silencing experiments revealed that these basal,
opposing pro- and anti-apoptotic functions of JNK1 and JNK2
are largely independent of up-stream kinases MKK4 and
MKK7. This was consistent with lack of discernable change in
JNK1 phosphorylation despite JNK1-dependent apoptosis fol-
lowing depletion of JNK2. Further experiments revealed that the
basal JNK1 pro-apoptotic pathway involves c-Jun plus compo-
nents of the TNFa-responsive MAP kinase pathway coupled with
the NFkB pathway via c-Jun-mediated down-regulation of Bcl-3.
Thus the basal regulation of cancer cell survival appears to be
dependent upon the opposing functions of JNK2/Bcl-3 (pro-
survival) and JNK1/c-Jun (pro-apoptotic) and to be under
constitutive control by JNK2.
Results
Selective knock-down of JNK2 enhances JNK1 expression
For RNAi we employed synthetic siRNAs under conditions
previously demonstrated to give efficient knock-down of target
mRNAs without activation of the p53 cellular stress response [21,22].
RNAi controls included BCR-ABL siRNA, which has no mRNA
target in epithelial cells and therefore serves as a non-functional
siRNA control, and lamin A/C siRNA, which targets lamin A/C
mRNA and serves as a functional siRNAcontrol (Methods).Selective
knock-down of JNK1 and JNK2 mRNA was reproduced with two
differentsiRNAsfor each target (MethodsandFig. S1). Theefficiency
of mRNA knock-down was determined by quantitative PCR and was
similar for both JNK1 and JNK2 (,75% reduction; see Fig. 1A for
JNK1 mRNA levels). RNAi-induced silencing of lamin A/C or of
JNK1 did not induce any change in p53 or p21
WAF1,ap 5 3 -
dependenttargetgene(Fig.1BforJNK1siRNAandFig.S2forlamin
A/C siRNA), thus confirming that the conditions of RNAi per se do
not initiate a p53 stress response. However JNK2 silencing resulted in
a ,3 fold increase in p53 protein (Fig. 1B) suggesting that JNK2
directly or indirectly regulates the turnover of p53 protein. This is
consistent with the report that JNKs can regulate the basal turnover
of p53 [23]. Interestingly, co-silencing of JNK1 with JNK2 abrogated
the rise in p53 (Fig. 1B) implying that JNK1 and JNK2 exert co-
ordinated effects upon the turnover of p53.
Unexpectedly, in HCT116 colorectal cancer cells JNK2 knock-
down consistently resulted in a ,50% increase in JNK1 mRNA
levelsand a ,3 foldincreaseinJNK1proteinlevels (Fig. 1A and 1B).
Similar results for JNK1 mRNA were obtained in isogenic HCT116
p53
+/+ and HCT116 p53
2/2 cells (Fig. 1A and 1B), indicating that
theeffectisp53-independent.Thus,inHCT116cells,thepresenceof
JNK2 directly or indirectly suppresses basal JNK1 expression levels.
JNK2 knock-down induces apoptosis
Knock-down of JNK2 resulted in apoptosis in a range of cancer
cell lines including HCT116 cells (Fig. 1C and 1D). Apoptosis was
determined by annexin V staining (Methods) and involved pro-
caspase 8 activation and effector caspases 3 and 7 (Fig. 1E). This
apoptotic effect of JNK2 depletion was independent of p53 as
evidenced by HCT116 p532/2 cells (Fig. 1C and 1D). In non-
cancer cells JNK2 silencing did not induce apoptosis (ARPE19 and
MCF10A epithelial cells, and WI-38 fibroblasts) despite efficient
JNK2 mRNA knock-down (Fig. 1D and data not shown). In
contrast to JNK2 silencing, the silencing of JNK1 did not affect
viabilityin any ofthe cell lines tested(Fig.1C and 1D). Overall these
results indicate that JNK2, but not JNK1, is essential for basal
viability in a number of human cancer cell lines including MCF7
breast cancer epithelial cells, but is dispensable for basal viability of
non-cancer cells including MCF10A breast epithelial cells.
Apoptosis is JNK1-dependent
We next co-silenced JNK1 with JNK2 in order to investigate
their functional linkage in the regulation of cancer cell survival. In
all cases where JNK2 silencing induced apoptosis we found that
co-silencing JNK1 with JNK2 rescued JNK2-depleted cells from
apoptosis (Fig. 1D). Thus we conclude that JNK1 and JNK2
counter-balance each other in the maintenance of cancer cell
viability and that JNK2 constitutively suppresses JNK1-mediated
apoptosis under basal conditions.
JNK1-dependent apoptosis is independent of enhanced
JNK1 S63/73 phosphorylation
The above results indicate that JNK1 is primed to induce
apoptosis in human epithelial cancer cells but is constitutively
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mediators of the MAP kinase apoptotic pathway and are activated
in response to stress by MKK4 and/or MKK7 phosphorylation at
T183/Y185 (Introduction). We next compared JNK1 and JNK2
phosphorylation under basal (RNAi) and stress-induced (UV or
TNFa) conditions.
As expected UV irradiation induced strong phosphorylation at
residues T183/Y185 of both JNK1 and JNK2 proteins in
HCT116 cells (Fig. 2A). Similarly, treatment of HCT116 cells
with TNFa also induced JNK1 and JNK2 phosphorylation at
T183/Y185 (Fig. 2B, upper panel). In this latter instance JNK1
phosphorylation predominated over JNK2 phosphorylation.
These results clearly demonstrate phosphorylation of JNK1 and
JNK2 in response to genotoxic stress (UV) and to receptor-
mediated stress (TNFa) in HCT116 cells. Both UV-irradiation
and TNFa induced apoptosis (data not shown).
Under basal conditions, when JNK1 was actively pro-apoptotic
following JNK2 silencing, there was no discernable increase in
JNK1 T183/Y185 phosphorylation (Fig. 2A, compare control
lane with JNK2 siRNA lane). This is in striking contrast to stress-
induced conditions (Fig. 2A; compare JNK2 siRNA lane with UV
lane). Thus we infer that JNK1 is able to promote apoptosis in the
absence of ‘activating’ T183/Y185 phosphorylations that are
characteristically induced in response to stress. Co-silencing up-
stream kinases MKK4 or MKK 7 with JNK2 only partially
rescued JNK1-dependent apoptosis (Fig. S3), further substantiat-
ing the ability of JNK1 to promote apoptosis in the absence of
enhanced T183/Y185 phosphorylations.
We conclude that, under basal conditions, JNK1 can actively
promote apoptosis without undergoing enhanced T183/Y185
phosphorylation characteristic of the cellular stress response. This
basal pro-apoptotic function of JNK1 is evident in human
epithelial cancer cells (but not in non-cancer cells) and is
constitutively inhibited by endogenous JNK2. To investigate the
basal apoptotic pathway under JNK1 control we next carried out a
series of co-silencing experiments aimed at identifying essential
pro-apoptotic mediators linked with the JNK1-dependent apopto-
sis following JNK2 silencing.
c-Jun is an essential mediator of basal apoptosis and is
subject to opposing effects of JNK1 and JNK2
To ask if c-Jun is required for apoptosis under basal conditions
we co-silenced c-Jun with JNK2 (Fig. 2; the efficiency of c-Jun
mRNA knockdown is shown in Fig. 2G). The results clearly
demonstrate that c-Jun co-silencing rescues JNK2-silenced
HCT116 cells from apoptosis thus identifying c-Jun as an essential
mediator of apoptosis subject to JNK2 suppression under basal
conditions (Fig. 2C).
Figure 1. JNK2 constitutively suppresses JNK1-mediated apoptosis in a range of human cancer cell lines but not in non-cancer cells.
(A) JNK1 mRNA levels, and (B) JNK1, JNK2, and also p53 and p21 protein levels determined 48 h after transfection with JNK1- and JNK2-siRNAs as
indicated (Methods). (C) Phase contrast images of HCT116 cells 48 h after transfection with JNK1- and JNK2-siRNAs. (D) Apoptosis determined by
annexin V labelling of siRNA-treated cells relative to untreated controls in a range of human cell lines (Methods. Note: apoptosis results are
representative of at least three repeat experiments unless error bars are included for repeat analyses of a single experiment). (E) Caspase 8 and its
cleavage products, activated caspase 7 and effector caspase 3 following RNAi-mediated silencing of JNK1 and JNK2 as indicated. Actin = loading
controls. HCT116 p53+/+ and HCT116 p532/2 are isogenic clones of human HCT116 colorectal cancer cells (Methods).
doi:10.1371/journal.pone.0007305.g001
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silencing in HCT116 cells (Fig. 2D; increased c-Jun was also
observed in RKO and Lovo cells following JNK2 silencing, not
shown) paralleled by an increase in c-Jun mRNA (Fig. 2E).
Interestingly, this effect was abolished when JNK1 was co-silenced
with JNK2 (Fig. 3A for c-Jun protein and Fig. 2E for c-Jun
mRNA) indicating that up-regulation of c-Jun is dependent upon
the continued presence of JNK1. JNK1 silencing alone caused a
decrease in c-Jun mRNA and protein (Fig. 2E and Fig. S4). These
combined observations indicate that JNK1 and JNK2 exert
opposing effects upon c-Jun expression and that JNK1 is required
for maintenance of basal c-Jun mRNA and protein expression
levels, whilst JNK2 constitutively suppresses c-Jun mRNA and
protein expression levels. Similar results were observed in
HCT116 p53
+/+ and HCT116 p53
2/2 cells (see for example
Fig. 2E). Interestingly increased c-Jun mRNA levels were not
observed in JNK2-silenced ARPE19 cells (Fig. 2F) consistent with
lack of apoptosis in these cells (Fig. 1D).
Our results identify opposing effects of JNK1 and JNK2 on
c-Jun. In this respect they differ from observations obtained using
a ‘chemical genetics’ approach in which the catalytic ATP-binding
pocket of JNK2 was expanded by mutation [2]. The conclusion
from this latter approach was that JNK1 and JNK2 both positively
regulate c-Jun expression. However, it is possible that expansion of
the ATP-binding pocket of JNK2 may perturb the spatial
molecular organisation of the adjacent b-strand-like region of
JNK2 protein. Since this b-strand-like domain is important for
JNK2 protein-protein interactions we suggest that localised
perturbation at this site may compromise the binding character-
istics of JNK2 protein for its target substrates. This might affect the
functioning of mutant JNK2 in ways additional to the predicted
effects on molecular access into the expanded ATP binding pocket
of JNK2.
Another study comparing murine fibroblasts derived from
JNK12/2 and JNK22/2 mice indicated that JNK1 and JNK2
can function as opposing regulators of c-Jun [3]. Our own results,
under basal conditions, are consistent with this report and show
that in HCT116 cells (i) JNK2 silencing results in up-regulation of
c-Jun mRNA accompanied marked accumulation of c-Jun protein,
and (ii) up-regulation of c-Jun under these conditions is dependent
upon JNK1.
Up-regulation of JNK1 in JNK2-depleted cells is
independent of c-Jun
Given that basal up-regulation of c-Jun (in JNK2-depleted cells)
requires JNK1 (see above) we wondered if c-Jun, in its turn, is
required for the up-regulation of JNK1 protein following JNK2
silencing (Fig. 1B). However the increase in JNK1 consistently
observed in JNK2-silenced cells was unaffected by co-silencing
c-Jun with JNK2 (Fig. 2D; upper panel). This indicates that
enhanced mRNA and protein expression of JNK1 following JNK2
depletion is independent of c-Jun.
Figure 2. JNK1 and c-Jun, required for basal apoptosis, remain hypo-phosphorylated following JNK2 silencing whereas both are
hyper-phosphorylated in response to stress. (A) Comparison of JNK1/JNK2 phosphorylation status in control, JNK2-silenced and following UV-
irradiation (HCT116 cells; Methods). p-JNK1 = phosphorylated JNK1, pJNK2 = phosphorylated JNK2 (arrowed). (B) Effects of TNFa on
phosphorylation status of JNK1, JNK2 and c-Jun. (C) Co-silencing c-Jun with JNK2 rescues HCT116 cells from apoptosis (annexin V labelling; Methods).
(D) JNK1, JNK2 and c-Jun protein levels 48 h post RNAi-mediated silencing of JNK2 and c-Jun. P53 and p21 protein levels are also shown. (E) c-Jun
mRNA levels after JNK1 and JNK2 silencing. (F) Fold increase in c-Jun mRNA levels in HCT116 cells compared with ARPE19 cells 48 h after JNK2
silencing. (G) Knockdown of c-Jun mRNA and protein levels in HCT116 p53+/+ cells following c-Jun siRNA treatment.
doi:10.1371/journal.pone.0007305.g002
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Stress-induced S63/S73 phosphorylation of c-Jun by JNK
kinases releases c-Jun from an inhibitory complex thus enabling
c-Jun to bind and transactivate target promoters [24]. Stress-
induced phosphorylation of c-Jun in HCT116 cells treated with
UV-irradiation isshowninFig.3A.However,althoughweobserved
high accumulation of c-Jun protein following JNK2 silencing
(Fig. 3A; JNK2 siRNA lane) this was independent of increased N-
terminal phosphorylation at S63, S73 or at S91 (Fig. 3A).
JNK2 silencing induces a marked increase in c-Jun mRNA
levels (see above, Fig. 2E). To ask if increased c-Jun transcripts
were attributable, at least in part, to a positive auto-regulatory
feed-back loop we performed chromatin immunoprecipitation
(ChIP) for c-Jun/c-Jun promoter complexes (Fig. 3B and 3C). In
untreated HCT116 cells c-Jun was undetectable at the c-Jun
promoter (Fig. 3C, controls). Following UV-irradiation c-Jun was
phosphorylated at S63 and S73 (Fig. 3A) and the phosphorylated
protein was bound at the c-Jun promoter as indicated by ChIP
analysis using anti-phospho-T63/73 c-Jun antibodies (Fig. 3C). In
JNK2-depleted cells, under basal conditions, no change in c-Jun
T63/73 phosphorylation was evident relative to the controls
(Fig. 3A). Nonetheless c-Jun in these cells was bound at the c-Jun
promoter (Fig. 3C). Lack of phosphorylation of the chromatin-
bound c-Jun was confirmed by lack of reactivity with anti-
phospho-T63/73 c-Jun antibodies (Fig. 3C; compare samples
from UV-irradiated cells with JNK2-silenced cells). Thus we
conclude that S63/73 hypo-phosphorylated c-Jun binds to its own
promoter following JNK2 depletion and is likely to contribute to
the high c-Jun mRNA expression levels (,9-fold increase over
control, see Fig. 2E) induced under these basal conditions.
c-Jun protein accumulation correlates with loss of
phosphorylation at S243
It is possible that c-Jun is maintained at low levels in HCT116
cells, lower than observed for non-cancer ARPE19 cells (data not
shown), via continual c-Jun protein degradation. Degradation of
c-Jun involves C-terminal phosphorylation at S243 which primes c-
Jun for GSK3-mediated phosphorylation at T239. This generates
an attachment site for the Fbw7 E3 ubiquitin ligase, resulting in
polyubiquitinylation and c-Jun degradation [10]. In our present
study we noted that JNK1 silencing caused a slight but reproducible
increase in c-Jun S243P (see Fig. 4B–4D; control lane cp JNK1
siRNA lane S243P immunoblots). Conversely JNK2 silencing
reproducibly caused reduced levels of c-Jun 243P, sometimes
undetectable despite massive accumulationof total protein(Fig. 4B–
4D; control lane cp JNK2 siRNA for S243P immunoblots). Thus
JNK1 and JNK2 exert opposing effects upon c-Jun phosphorylation
at S243, a modification linked with de-stabilisation of c-Jun protein.
GSK3, ERK, Fbw7 and ITCH are essential mediators of
basal JNK1-dependent apoptosis
In a further series of co-silencing experiments we demonstrate
that kinases GSK3, ERK, and the ubiquitin 3 ligase Fbw7 are also
essential mediators of JNK1-dependent apoptosis in JNK2-
depleted cells (Fig. 4E). However none of these components
appeared to impinge upon S243 phosphorylation or accumulation
of the c-Jun protein (Fig. 4B, 4C and 4D; lanes GSK3, Fbw7 and
ERK respectively). This was unexpected since, in response to
stress, all three have been linked with c-Jun degradation via S239
and S243 phosphorylation (ERK and GSK3 respectively) and
ubiquitin-mediated degradation (Fbw7) [10,25,26]. It seems that,
under basal conditions, GSK3, ERK and Fbw7 function as
essential mediators of apoptosis via substrates other than c-Jun.
Bax and CKII are dispensable for the basal JNK1/JNK2
apoptotic pathway
Following stress Bax is a pro-apoptotic mediator of JNK-
induced apoptosis [27,28]. To ask if Bax is also required for the
basal JNK1/JNK2-regulated apoptotic pathway we used isogenic
Bax+/2 and Bax2/2 HCT116 cells [2]. JNK2 silencing induced
apoptosis in both HCT116 Bax
+/2 and HCT116 Bax
2/2 cells
(Fig. 4F) indicating that Bax is not required for apoptosis under
these basal conditions. Co-silencing CKII, a putative kinase for c-
Jun [3], also failed to rescue JNK2-depleted HCT116 cells from
apoptosis (Fig. 4E). Thus both Bax and CKII appear dispensable
for the basal JNK1/JNK2 apoptotic pathway.
Interaction between c-Jun and ITCH
The pro-apoptotic pathway induced by TNFa culminates in
phosphorylated JNK1-dependent activation of ITCH, degradation
Figure 3. Hypo-phosphorylated c-Jun protein accumulates to high levels following JNK2 silencing, this effect is dependent upon
JNK1 and correlates with c-Jun chromatin binding at the c-Jun promoter in HCT116 cells. (A) Total c-Jun protein and phosphorylations at
S63, S73 and T91 following either UV-irradiation (right hand lane) or JNK1 and JNK2 RNAi-induced silencing. (B) Schematic showing c-Jun and the
amplicon used for detecting c-Jun on the promoter. (C) Total and phosphorylated forms of c-Jun bound at the c-Jun promoter detected by chromatin
immunoprecipitation (ChIP) with c-Jun and c-Jun phospho-specific antibodies. Histogram shows fold-enrichment relative to IgG controls (Methods).
doi:10.1371/journal.pone.0007305.g003
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that ITCH is also an essential pro-apoptotic mediator governed by
JNK1/JNK2 under basal conditions and that co-silencing ITCH
with JNK2 rescues cells from apoptosis (Fig. 5A and 5B).
To further investigate the pro-apoptotic role of ITCH under
basal conditions we performed immunoprecipitation/immunoblot
analysis for endogenous complexes of ITCH-c-Jun before and
after RNAi-mediated silencing of JNK2 (Fig. 5C). Significantly,
ITCH-c-Jun complexes were detectable under control conditions
but these complexes were lost following JNK2 silencing (Fig. 5C).
Apoptosis proceeds via c-FLIP and caspase 8
Co-silencing caspase 8 with JNK2 rescued cells from apoptosis
(Fig. 4E). This effect was restricted to basal conditions since caspase
8 RNAi failed torescue apoptosis followingUV irradiation (datanot
shown). c-FLIP silencing alone induced apoptosis in HCT116 cells
[29]. Co-silencing c-Jun, GSK3, or Fbw7 with c-FLIP failed to
rescue cells from apoptosis (Fig. 6A), indicating that each of these
pro-apoptotic intermediates function up-stream of c-FLIP (Fig. 7A-
schematic). Thus basal and stress-induced apoptotic MAP kinase
pathways converge at the level of c-FLIP. As expected, co-silencing
caspase 8 with c-FLIP rescued cells from apoptosis (Fig. 6A and 6B).
Over-expression of exogenous c-Jun induces apoptosis
We next asked if high level expression of c-Jun alone is sufficient
to induce apoptosis. Over-expression of exogenous wild type c-Jun
induced apoptosis in HCT116 cancer cells (Fig. 7A and 7B).
Importantly, over-expression of a c-Jun phosphorylation mutant,
in which S63, S73, T91 and T93 are all mutated to alanine, also
induced apoptosis thus re-enforcing evidence for pro-apoptotic
functions of hypo-phosphorylated c-Jun (Fig. 7A and 7B). Note
that exogenous expression of another protein, SIRT1, does not
induce apoptosis in HCT116 cells [22] indicating that the present
results are specific to c-Jun. Protein expression from the c-Jun
constructs and phosphorylation status shows phosphorylation at all
sites examined on wild type c-Jun (Fig. 7C). This is indicative of
cellular stress in response to exogenous gene over-expression. Note
that this is in contrast to the sustained c-Jun hypo-phosphorylated
status following RNAi-mediated gene silencing under the basal
conditions employed throughout this work (see for example
Fig. 3A). The c-Jun phosphorylation mutant lacked reactivity
with anti-phospho-S63, S73 and T91 antibodies as expected
(antibody to phosphoserine 93 was not available). Although both
mutant and wild type exogenous c-Jun proteins were phosphor-
ylated at T239 and S243 (Fig. 7C) we believe that this was non-
essential for induction of apoptosis since endogenous c-Jun is
required for apoptosis despite lack of C-terminal phosphorylation
(see for example Fig. 4B-4D following JNK2 silencing). Signifi-
cantly, over-expression of exogenous c-Jun did not induce
apoptosis in non-cancer ARPE19 cells (Fig. 7B). These overall
observations further re-enforce our conclusions (i) that elevated
levels of hypo-phosphorylated c-Jun are pro-apoptotic in HCT116
Figure 4. GSK3, ERK and Fbw7 are essential basal pro-apoptotic mediators following JNK2 silencing but are without apparent effect
upon their stress-associated substrate c-Jun. (A) Schematic showing sites of phosphorylation of c-Jun by JNK, GSK-3 and ERK, and their respective
functional consequences. Note that S243P is a pre-requisite of T239 phosphorylation (indicated by curved arrow). (B) Immunoblots showing effects of
JNK1, JNK2 and GSK3 silencing, alone and in combinations, on a panel of HCT116 cellular proteins. (C) and (D) Immunoblots following combinatorial
silencing of JNK1 and JNK2 with Fbw7 and ERK. (E) Essential pro-apoptotic intermediates determined by co-silencing with JNK2. (F) Apoptosis following
JNK2 silencing under basal conditions is independent of Bax as evidenced by Bax+/2 and Bax2/2 HCT116 isogenic clones.
doi:10.1371/journal.pone.0007305.g004
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(HCT116) and is not observed in non-cancer cells (ARPE19).
Effects of c-Jun silencing are not attributable to off-target
effects of c-Jun siRNA
The ability to rescue JNK2-depleted cells from apoptosis by
combinatorial siRNA-induced gene silencing is strong evidence
that our above results reflect specific gene silencing rather than
general off-target effects of RNAi. This was confirmed for c-Jun by
selective RNAi-targetting of endogenous wild type c-Jun in cells
expressing an exogenous pro-apoptotic c-Jun mutant lacking a
complementary mRNA recognition site for the c-Jun siRNA
(Methods). For this purpose we used the c-Jun phosphorylation
mutant already shown to be pro-apoptotic in HCT116 cells (see
above; Fig. 7A and 7B). As before, JNK2 silencing alone induced
apoptosis whilst co-silencing JNK2 with endogenous c-Jun rescued
HCT116 cells from apoptosis (Fig. 7D). However, in those cells
expressing the exogenous non-target c-Jun mRNA, wild-type
c-Jun/JNK2 co-silencing failed to rescue cells from apoptosis
(Fig. 7D). These results confirm that the observed effects of c-Jun
silencing are attributable to selective gene silencing rather than to
non-selective off-target effects of RNAi.
Non-phosphorylated c-Jun accumulates in the insoluble
nuclear fraction following JNK2 silencing
JNK2 silencing results in high level accumulation of non-
phosphorylated c-Jun in HCT116 cancer cells (see above). Cell
fractionation studies revealed that most, if not all, of the non-
phosphorylated c-Jun protein accumulates in the nuclei of JNK2-
silenced cells and selectively associates with the insoluble nuclear
fraction (Fig. 8A). Prior to JNK2 silencing the c-Jun protein,
present at low levels in HCT116 cells, predominated in the
nucleoplasmic fraction (Fig. 8A). The accumulated hypo-phos-
phorylated c-Jun was physically separated from GSK3 and ERK,
two kinases that can phosphorylate c-Jun (see Introduction), and
also from ITCH, an E3 ligase involved in JNK1-mediated
Figure 5. c-Jun is complexed with ITCH under basal condition and released following JNK2 silencing. (A) and (B) Protein and apoptotic
levels observed following ITCH and JNK2 silencing in HCT116 cells. (C) Complexes of endogenous ITCH-c-Jun proteins detected prior to JNK2
silencing are lost following JNK2 depletion.
doi:10.1371/journal.pone.0007305.g005
Figure 6. c-FLIP is an essential mediator of basal apoptosis in human cancer cells and functions downstream of GSK3, Fbw7, c-Jun
and JNK1. (A) Levels of apoptosis observed following co-silencing of c-FLIP with pro-apoptotic mediators. (B) Protein levels showing pro-caspase 8
cleavage and c-Jun accumulation following c-FLIP depletion by RNAi.
doi:10.1371/journal.pone.0007305.g006
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cytoplasmic fraction both before and after depletion of JNK2
(Fig. 8A). For ERK some additional protein was detectable in the
soluble nuclear fraction following JNK2 silencing (Fig. 8A). The
localisation of NFkB family members also showed little change
following JNK2 silencing with the exception of p65 which showed
some binding within the nuclear fraction (Fig. 8A). The insoluble
nature of c-Jun’s nuclear localisation following JNK2 silencing
Figure 7. c-Jun overexpression induces apoptosis in HCT116 p53+/+ cells but not in ARPE-19 cells. (A) Schematic showing wild type c-
Jun (wt-c-Jun) and non-phosphorylatable mutant c-Jun constructs. (B) Annexin V measurement of apoptosis following overexpression of wt-c-Jun or
mut-c-Jun as indicated. (C) Immunoblots showing total and phosphorylated c-Jun following overexpression, SIRT1 loading control shown. (D) Levels
of apoptosis following combined siRNA treatment in the presence or absence of non-target mut-c-Jun, (see materials and methods).
doi:10.1371/journal.pone.0007305.g007
Figure 8. Non-phosphorylated c-Jun accumulates in the insoluble nuclear fraction following JNK2 silencing and down-regulates
Bcl-3 expression in HCT116 p53+/+ cells. (A) Nuclear and cytoplasmic preparations following control and JNK2 siRNA treatment. Immunoblots
show protein levels in the fractions indicated, equivalent cell number per lane. Histone H3 (nuclear insoluble) and 14-3-3s (cytoplasmic) fractionation
controls. (B and C) Quantitative PCR analysis of Fas and Bcl-3 mRNA. (D) Bcl-3 protein levels following siRNA treatment. (E) Levels of apoptosis
following Bcl-3 or combined Bcl-3 and c-Jun siRNA treatment. (F) Immunoblots showing levels of Bcl-3 following siRNA treatment.
doi:10.1371/journal.pone.0007305.g008
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complexed with sub-nuclear structures and/or chromatin. This is
likely to include hypophosphoryated c-Jun bound at the c-Jun
promoter (see above and Fig. 3). Non-cancer ARPE19 cells
showed different sub-cellular localisations compared with
HCT116 cancer cells in that c-Jun and Bcl-3 proteins were
localised in the nuclear soluble and insoluble fractions under basal
conditions (Fig. 8A and Fig. S5).
JNK2 enhances, whilst c-Jun suppresses expression of
Bcl-3, a pro-survival IkB protein
In an attempt to identify down-stream targets of JNK2/c-Jun we
next screened for AP-1 targets reciprocally responsive to JNK2 and
c-Jun silencing but with little or no response to combined JNK2 plus
c-Jun co-silencing. We identified two AP-1 targets as fitting these
criteria:namelyFASand Bcl-3 (Fig.8B and 8C).It iswellestablished
that FAS is pro-apoptotic and, consistent with this, FAS expression
was up-regulated upon JNK2 silencing, down-regulated upon c-Jun
silencing, and these opposing effects were cancelled following JNK2
plus c-Jun co-silencing (Fig. 8B and 8C). These results indicate that
up-regulation of FAS following JNK2 silencing is c-Jun-dependent.
In contrast Bcl-3 appeared to be down-regulated by c-Jun. Thus,
c-Jun silencing resulted in increased Bcl-3 expression whilst JNK2
silencing correlated with Bcl-3 down-regulation (Fig. 8C and 8D).
JNK1 silencing also increased Bcl-3 (Fig. 8F) consistent with its
positive role in basal c-Jun functions. Bcl-3 down-regulation was
clearly dependent upon c-Jun since co-silencing c-Jun with JNK2
negated their opposing effects on Bcl-3 expression (Fig. 8C and 8D).
Thus JNK-2 silencing in HCT116 cancer cells causes down-
regulation of Bcl-3 expression and this effect is mediated via c-Jun.
Bcl-3 and c-Jun are pivotal in basal cancer cell survival
Since Bcl-3 has been implicated in abnormal cell survival we
next asked if Bcl-3 is required for the survival of HCT116 cancer
cells. RNAi-mediated silencing of Bcl-3 induced apoptosis in
HCT116 cells (Fig. 8E). This effect could not be rescued by co-
silencing c-Jun (Fig. 8E), indicating that the pro-survival function
of Bcl-3 is down-stream of c-Jun. Our results suggest that the c-Jun
pro-apoptotic mechanism operates, at least in part, via c-Jun-
dependent down-regulation of Bcl-3. These observations are
important and link the basal JNK2-mediated regulation of cancer
cell survival with the NFkB pathway and identify c-Jun and Bcl-3
as reciprocal pivotal determinants of apoptosis versus survival
respectively.
Discussion
Basal apoptosis versus stress-induced apoptosis
The programmed regulation of apoptosis under basal physio-
logical conditions is crucial for normal mammalian development
and, in the adult, for normal cellular turnover in individual tissue
types. A further level of apoptotic control is induced in response to
stress. Indeed, much of our understanding of the regulation of
apoptosis in mammalian cells is based upon studies in which cells
are analysed following exposure to defined stress conditions. From
such studies it is becoming clear that different apoptotic programs
are induced by different stimuli and are governed by cell type and
physiological context [30].
In contrast to stress-induced apoptosis, the intrinsic regulation of
apoptosis under basal conditions is poorly understood. To address
this problem we have investigated cells in the absence of applied
stress and explored the regulatory balance governing basal cell
survival versus apoptosis. Such information is particularly
important for understanding disease processes including cancer
in which regulatory failure of basal apoptosis permits de-regulated
growth and survival of cells in vivo.
Basal cancer cell survival involves a novel apoptotic
network
Our results indicate that JNK2 is required for the survival of a
range of human cancer cells cultured in the absence of applied
stress. They also place JNK2 upstream of a novel regulatory
network in which apoptosis (i) is driven by co-ordinated pro-
apoptotic functions of JNK1 and c-Jun, (ii) is primed under basal
conditions, (iii) is constitutively suppressed by JNK2, (iv) is linked
with the NFkB survival pathway via Bcl-3/c-Jun, and (v) is
mechanistically distinct from stress-induced apoptosis (Fig. 9 and
Fig. 10). Moreover, the basal pro-apoptotic functions of JNK1 and
Figure 9. Basal survival of human cancer cells involves JNK2 suppression of a novel pro-apoptotic pathway. (A) JNK2 constitutively
represses JNK1-mediated apoptosis. JNK1 is primed to initiate apoptosis which proceeds via the indicated intermediates (see Results). c-Jun
dissociates from ITCH upon JNK2 depletion, loses S243P (*) and up-regulates its own transcription (N). (B) Distinctive characteristics of components of
the MAP kinase pathway operating under basal conditions indicate that the regulation of apoptosis under basal conditions is mechanistically distinct
from stress-induced apoptosis.
doi:10.1371/journal.pone.0007305.g009
Basal Regulation of Apoptosis
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7305c-Jun appear active despite the absence of site-specific phosphor-
ylations known to be required for activation in response to stress.
Following JNK2 depletion hypo-phosphorylated c-Jun protein
translocates to the nucleus where it accumulates in the insoluble
fraction and autoregulates its own expression. These changes in
c-Jun are dependent upon hypo-phosphorylated JNK1 (Results
and Fig. 9).
Downstream mediators of the basal pro-apoptotic pathway
include components of the TNFa response pathway, namely
ITCH, GSK3, ERK and Fbw7. However their functional
interactions appear to be mechanistically distinct from those
induced by stress (Results). This indicates that the regulation of
basal cell survival/apoptosis is distinct from stress-induced
apoptosis even though the same pro-apoptotic players are
employed. It is possible that as yet uncharacterised protein-protein
interactions govern basal apoptotic functions of hypo-phosphor-
ylated JNK1, JNK2 and c-Jun. Such interactions may enable the
formation of multi-protein complexes and basal apoptotic
pathways distinct from those induced by stress.
Our results also indicate that the basal pro-apoptotic pathway is
countered by the IkB protein Bcl-3. Once again JNK2 is the
master regulator (Fig. 10). Mechanistically this is attributable to
JNK2-mediated suppression of c-Jun, which we identify as down-
regulator of Bcl-3 expression in HCT116 cancer cells. JNK2
depletion results in accumulation of c-Jun protein which, in turn,
down-regulates Bcl-3 mRNA and protein levels (Results). Down-
regulation of Bcl-3 directly impacts upon cell survival since we also
demonstrate that RNAi-mediated depletion of Bcl-3 induces
apoptosis despite the continued presence of JNK2 (Results).
The involvement of Bcl-3 in the basal regulation of cancer cell
survival versus apoptosis is particularly interesting, especially since
Bcl-3 is already identified as a putative oncoprotein [18,31,32,33].
Bcl-3 has an atypical domain structure for an IkB protein. This
confers distinct functional properties for Bcl-3. For example, in
contrast to IkBa and IkBb, the nuclear localisation signal on Bcl-3
lies outside the ankyrin repeat domain and enables transport of
bound p50:p50 NFkB homodimers into the nucleus ([17] and
references therein). Also, the seventh ankyrin repeat of Bcl-3,
Figure 10. Basal regulation of apoptosis involves a novel network regulated by JNK2 and mediated via JNK1, c-Jun and Bcl-3.
Hypothetical model for acquisition of an intrinsic apoptotic network in intestinal epithelial cells as they approach terminal differentiation. This
network is subject to JNK2 which, abnormally, can enable cell survival and cancer via constitutive suppression of down-stream pro-apoptotic
mediators under JNK1 control (see Discussion and Fig. 9).
doi:10.1371/journal.pone.0007305.g010
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candidate for interaction with the minor groove of DNA [17],
possibly accounting for Bcl-3 complexing with DNA-bound NFkB
homodimers.
The functional significance of Bcl-3 is unknown. Our discovery
that this unusual IkB protein is reciprocally linked with JNK1/
c-Jun in the basal regulation of apoptosis raises the possibility that
Bcl-3 may function selectively under basal physiological condi-
tions. Thus, during evolution, the functioning of Bcl-3 and IkBa/
IkBb may have diverged to regulate cell survival under basal
versus stress-induced conditions respectively.
Cancer versus non-cancer cells
Comparison of cancer and non-cancer cell lines indicates that
the JNK2 requirement for cell survival is restricted to cancer cells
(Results and Fig. 1). This is consistent with the reported viability of
JNK22/2 mice (Introduction). For more in-depth comparison of
cancer versus non-cancer cells we used HCT116 p53+/+ and
ARPE19 cell lines. HCT116 p53+/+ are well characterised
human epithelial colorectal cancer cells and have a stable
karyotype. ARPE19 cells are partially differentiated retinal
pigmented epithelial cells derived from non-cancerous tissue.
ARPE19 have a normal karyotype and retain many of the
structural and physiological properties of normal retinal pigment-
ed epithelial cells in vivo [34], including polarised membrane
expression of monocarboxylate transporters [35].
Our results demonstrate that HCT116 cancer cells are primed
to undergo basal apoptosis in response to (i) JNK2 depletion, (ii)
Bcl-3 depletion or (iii) exogenous over-expression of c-Jun. In
contrast the ARPE19 non-cancer cells were refractory to each of
these three conditions. These cancer-related differences may
reflect differences in sub-cellular localisations of pro- and anti-
apoptotic proteins such as c-Jun and Bcl-3 in cancer versus non-
cancer cells (see Results, Fig. 8 and Fig. S5). Cancer-related
differences in spatial proteomic fluxes may also influence the
balance between pro- and anti-apoptotic effectors under basal
conditions.
Another possibility is that altered metabolism and aerobic
glycolysis, characteristic of cancer cells [36], also impact upon pro-
and anti-apoptotic systems. In this context it is interesting to note
that nucleolar JNK2 and SIRT1 proteins are both responsive to
metabolic stress [37,38] and both are also identified as cancer-
related survival factors ([21,22,39,40] and this present work).
SIRT1 is an NAD-dependent de-acetylase and key regulator of
aging, metabolism and homeostasis [37,39]. SIRT1 protein
turnover appears subject to JNK2 in human cell lines [22]. As
yet the significance of this is unknown.
Cellular differentiation may also affect the balance of basal pro-
and anti-apoptotic networks. For example, normal intestinal
epithelial cells presumably become intrinsically primed to undergo
basal apoptosis as a part of the normal process of cellular turnover.
This process must be under stringent temporal control in order to
prevent premature apoptosis on one hand, and to prevent delayed
apoptosis and abnormal cellular accumulation on the other hand.
On the basis of our current observations we suggest that
components of the JNK and NFkB pathways may be exploited
and co-ordinated to achieve this effect. We hypothesise that the
basal JNK1/c-Jun pro-apoptotic pathway may be held in check by
JNK2 until terminal apoptosis is required (represented schemat-
ically in Fig. 10). We further propose that during earlier stages of
differentiation the JNK2/JNK1/c-Jun apoptotic network is non-
operational. This would minimise the risk of premature apoptosis
and also explain the observed resistance of undifferentiated non-
cancer cells (Results) to JNK2 silencing or over-expression of
c-Jun. However, at all stages of differentiation the cells are able to
respond to stress since they express JNK and NFkB pathways
which can be activated by stress-induced kinase signalling.
According to the above model for intrinsic apoptosis it is
predicted that failure to engage the basal JNK1/c-Jun pro-
apoptotic mechanism would compromise normal apoptotic
turnover and so favour tumour formation. Indeed, this is exactly
what is observed in JNK1-/- mice which exhibit pre-disposition to
intestinal tumour formation [20]. Failure to alleviate JNK2-
mediated suppression of JNK1/c-Jun would similarly favour
tumour formation, and this is supported by our evidence for
constitutive JNK2-mediated suppression of JNK1/c-Jun in a range
of human colorectal cancer cell lines (this paper).
In summary, the link between JNK2/JNK1/c-Jun and Bcl-3
identifies pivotal roles for these proteins in the basal regulation of
apoptosis versus cell survival. The discovery of a novel apoptotic
network governing basal cell survival is crucial for understanding
the intrinsic regulation of normal cellular turnover and opens new
avenues for therapeutic intervention in human proliferative disease
states.
Materials and Methods
Cell lines and transfection
Epithelial cancer cell lines used include human colorectal
carcinoma HCT116 isogenic clones (p53
+/+ and p53
2/2; Bax
+/2
and Bax
2/2) [2,41]; LoVo and RKO (wt p53), HT29 (mutant
p53); breast carcinoma: MCF7 (wt p53) and osteosarcoma: U2OS
(wt p53). Human non-cancer cell lines include ARPE-19 (retinal
epithelial) and WI-38 (lung fibroblasts) and MCF7 10A (breast
epithelial). MCF7 10A were grown in MEGM media supplement-
ed with 100 ng/mL cholera toxin in the absence of FCS. Other
cells lines were maintained and transfected using synthetic siRNAs
(Dharmacon) as described previously [21,22].
siRNA sequences and mRNA quantification
Two independent siRNA target, previously validated for JNK1
or JNK2 [22] were used. siRNA’s were typically used at a final
concentration of 100 nM. Additional siRNA and primer sequenc-
es are provided in the Supplementary Information S1. Total RNA
was isolated using RNeasy kit (Qiagen) following manufactures
protocol and mRNA levels was measured by quantitative PCR
using MJ DNA Engine Opticon with Qiagen SYBRgreen
Quantitect kit. At least three determinations of mRNA levels
were made.
Immunoprecipitation and Immunoblotting
For immunoblotting whole cell lysates were prepared and
processed in SDS buffer. Antibodies: anti-JNK1 (F-3), anti-c-Jun
(sc-45), anti-c-Jun-p63 (KM-1), anti-p53 (DO-1), GSK3 (sc-7291)
all Santa Cruz; JNK2, dual anti-phospho-SAPK/JNK (Thr
183,
Tyr
185), anti-cleaved caspase 3, anti-caspase 7, anti-caspase 8, anti-
c-Jun-p91, anti-c-Jun-p243, anti-FLIP, all Cell Signalling. Anti-c-
Jun-p239 antibody (Abcam) was unable to detect c-Jun-239
phosphorylation under basal conditions or following JNK2
silencing. Bcl-3 (C-14) from Santa Cruz; NFkB p65 (3034) and
NFkB p105/50 (3035) from Cell Signalling; ERK (9B3) and NFkB
p100/52 from Abcam. c-Jun Ser63 phosphorylation antibody
(KM-1, Santa Cruz). Anti-p21 (Pharmingen), anti-c-Jun-p73
(Upstate), and anti-ITCH (BD Transduction). Actin (AC40,
Sigma) was used as an internal loading control throughout all
experiments. Visualisation of bound antibodies was carried out
using enhanced chemiluminescence kit (Roche).
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p53+/+ cells were lysed in cold IP buffer (50 mM Tris pH 8,
150 mM NaCl, 1% NP40, 10 mM EDTA), in the presence of
protease cocktail inhibitor (Roche), sonicated and centrifuged. The
supernatant was percleared with protein G sephearse beads
(Sigma) followed by assay of total protein (BCA kit, Pierce). 800 mg
of total lysate was immunoprecipitated overnight at 4uC with 6 mg
of c-Jun antibody (sc-45, Santa Cruz). Controls included c-Jun
antibody with IP buffer only (no lysate), and IgG control.
Immunocomplexes were captured with protein G sephearse,
washed and eluted in denaturing SDS buffer. Eluates were
immunoblotted for ITCH (BD Transduction) and c-Jun (Upstate).
Chromatin Immunoprecipitation (ChIP)
ChIP was performed according to manufacturers protocol (EZ
ChIP, Upsate). HCT116 p53
+/+ cells were irradiated with
20 Jm
22 UV for 4 hours, or transfected with JNK2 siRNA for
48 hours. Additional details are provided in Supplementary
Information S1.
Stress treatment and apoptosis
Cells were treated with 20 Jm
22 UV for 4 h, or TNF-a
(Calbiochem) at final concentration of 20 ng/mL at time points
indicated. Apoptotic cells were identified by fluorescence activated
cell sorting (FACS) using Annexin V-Fluos (Roche). Caspase 8,
caspase 7 and caspase 3 were determined by immunoblotting.
Nuclear and Cytoplasmic Extraction
Nuclear and cytoplasmic extraction was carried out using NE-
PER kit (Pierce) according to manufactures instructions. Distribu-
tion of each protein is from a total of 750, 000 cells. The nuclear
insoluble fraction employs a different buffer to the nuclear soluble
fraction and accounting for slight changes in protein migration.
Plasmids and overexpression studies
Flag tagged wild type human c-Jun and mutant c-Jun constructs
have been described previously [10]. Mutant c-Jun contained
(S63/S73 and T91/T93R A substitutions). Transfection was
carried out with 1 mg of empty vector (PC3.1, control) or c-Jun
constructs as described previously [22] for 28 hours. Apoptosis was
detected using annexin V labelling as described earlier. For
combined overexpression and siRNA studies, cells were transfect-
ed with c-Jun (T91/93) siRNA as described earlier for 24 hours
followed by transfection of empty control vector or mutant c-Jun
construct (non recognisable to the siRNA, see Supplementary
Information S1) for 24 hours.
Supporting Information
Supplementary Information S1 Additional methods and
supporting references
Found at: doi:10.1371/journal.pone.0007305.s001 (0.05 MB
DOC)
Figure S1 JNK2 constitutively suppresses JNK1 mediated
apoptosis. Knock-down of JNK2 using a second independent
siRNA causes apoptosis. This is rescued by a co-silencing with a
second siRNA directed against JNK1. These results are consistent
with the JNK1 and JNK2 siRNA used this study, (see also
Materials and Methods).
Found at: doi:10.1371/journal.pone.0007305.s002 (0.58 MB TIF)
Figure S2 JNK1 and JNK2 levels are unaffected by BCR-ABL
or Lamin A/C siRNA treatment. Lamin A/C siRNA causes
specific knock-down of Lamin A/C without affecting JNK1/JNK2
levels. BCR-ABL siRNA (BCR) has no target in the cell lines used
in this investigation (negative control). The ‘‘stress sensor’’ p53 is
not activated following transfection of an active (Lamin A/C) or
inactive (BCR-ABL) siRNA.
Found at: doi:10.1371/journal.pone.0007305.s003 (1.06 MB TIF)
Figure S3 JNK upstream kinases MKK4 and MKK7 are
dispensable for JNK2 siRNA induced apoptosis in HCT116
p53+/+ cells. JNK2 siRNA mediated apoptosis was not rescued by
co-silencing with MKK4 and was only partially rescued following
combined MKK7 and JNK2 siRNA treatment.
Found at: doi:10.1371/journal.pone.0007305.s004 (0.99 MB TIF)
Figure S4 Knock-down of JNK1 causes attenuation of c-Jun
protein levels. The c-Jun blots in main figures have been under
exposed to measure induction of c-Jun.
Found at: doi:10.1371/journal.pone.0007305.s005 (0.99 MB TIF)
Figure S5 Apoptotic regulators fractionate into different com-
partments in ARPE-19 non-cancer cells. c-Jun and Bcl-3 localise
in both the nuclear soluble and nuclear insoluble fractions under
basal conditions compared to HCT116 p53+/+ cells where they
are found exclusively in the nuclear soluble fraction, (see Figure 8A
and Discussion).
Found at: doi:10.1371/journal.pone.0007305.s006 (1.18 MB TIF)
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